<?xml version="1.0" encoding="UTF-8"?>
<p id="p0075">
 <list list-type="simple" id="olist0010">
  <list-item id="o0010">
   <label>1.</label>
   <p id="p0080">
    <bold>Lack of awareness</bold> among the general population and high-risk groups, politicians and policymakers leads to low demand for testing and treatment and subsequent low demand for investment
   </p>
  </list-item>
  <list-item id="o0015">
   <label>2.</label>
   <p id="p0085">
    <bold>Stigma and discrimination</bold> reduce community demand for testing and treatment
   </p>
  </list-item>
  <list-item id="o0020">
   <label>3.</label>
   <p id="p0090">
    <bold>Weak surveillance systems and inadequate epidemiologic data</bold> result in limited data on the impact and cost burden of hepatitis B to drive investment
   </p>
  </list-item>
  <list-item id="o0025">
   <label>4.</label>
   <p id="p0095">
    <bold>Inadequate hepatitis B vaccination coverage, particularly birth dose</bold> leading to risk of transmission across the lifespan
   </p>
  </list-item>
  <list-item id="o0030">
   <label>5.</label>
   <p id="p0100">Limited access to affordable diagnostics, monitoring tests and treatment</p>
  </list-item>
  <list-item id="o0035">
   <label>6.</label>
   <p id="p0105">
    <bold>Inadequate health infrastructure and lack of integration of hepatitis B elimination programmes within existing health programmes</bold> including antenatal, infectious disease and chronic non-communicable disease programmes
   </p>
  </list-item>
  <list-item id="o0040">
   <label>7.</label>
   <p id="p0110">Lack of hepatitis-specific funding pools and lack of global investment in hepatitis B research &amp; development</p>
  </list-item>
 </list>
</p>
